Navigation Links
BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
Date:11/4/2013

JERUSALEM, Nov. 4, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease. The study is expected to begin by the end of this year.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

The Phase 1/2 study is a two-part (single and repeated), double-blind, placebo-controlled, dose escalation study of BL-7010 in up to 32 patients at a world-leading site for celiac disease research in Finland. The primary objective of the study is to assess the safety of single and repeated ascending doses of BL-7010 in well-controlled celiac patients. Secondary objectives include an assessment of the systematic exposure, if any, of BL-7010 in the study patients.

Professor Markku Maki, M.D., Ph.D., of the University of Tampere School of Medicine and the Tampere Center for Child Health Research in Finland, the responsible coordinating investigator of the trial, stated, "Celiac has become an increasingly problematic condition, with 1% of the world's current population suffering from this disease. The incidence of celiac is also expected to increase substantially in the future, with increased awareness and improved diagnostic tools. Despite the unmet medical need, the only current treatment is life-long adherence to a gluten-free diet, which is extremely difficult to maintain. Research results show that even up to 50% of patients on a gluten-free diet are still symptomatic and that small intestinal mucosal injury persists despite attempts t
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
2. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
3. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
4. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
5. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
6. BioLineRx to Present at 15th International Celiac Disease Symposium
7. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
8. BioLineRx Appoints B. J. Bormann to Board of Directors
9. BioLineRx Reports Second Quarter 2013 Results
10. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
11. ARRAYit Corporation Receives Purchase Order from ChemBio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... new market research report is available in its ... Electronic Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... fast-changing market for electronic medical records (EMR) for ... a comprehensive report of our findings. Our report ...
(Date:8/20/2014)... August 20, 2014 Glenmark ... Glenmark Pharmaceuticals Limited India (GPL), announces the discovery ... novel clinical development candidate, GBR 1302, a HER2xCD3 ... by the Glenmark Biologics Research Centre located in ... 1302 is based on Glenmark,s innovative BEAT antibody ...
(Date:8/19/2014)... Tenn. , Aug. 19, 2014   ... provide its patient experience technology to ... Under the five-year agreement, CarePoint Health will deploy ... Bayonne Medical Center, Christ Hospital and Hoboken University ... offers a range of software solutions to help ...
Breaking Medicine Technology:EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2
... 13 As biotechnology,pharmaceutical and medical device companies ... other parts of the world, such as Asia,Eastern ... firms, efforts to do business, according to an ... 2008 Clinical Trials Risk Map provides,those companies a ...
... MORRIS PLAINS, N.J., Aug. 13 Diakron Pharmaceuticals,Inc. ... agreement for a,novel investigational oral anticoagulant drug candidate ... Merck & Co. Inc. Under the,terms of the ... and,if approved, market and distribute the compound worldwide., ...
Cached Medicine Technology:Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc. 2
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... and architecture firm Perkins Eastman is pleased ... and design services in China and ... internationally recognized Principal Richard Sprow AIA has ... continue his 40-year career in healthcare planning and design ...
(Date:8/20/2014)... deadliest infectious diseases in the world, killing one to ... tuberculosis have long debated its origins. New research shows ... seals and sea lions that brought the disease to ... before Europeans landed on the continent. , The paper, ... New World Human Tuberculosis," was published in Nature ...
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
(Date:8/20/2014)... 20, 2014) Research from Columbia University Medical Center ... stomach cancer growth and that blocking nerve signals using ... for the disease. The study was conducted by the ... Duan Chen, MD, PhD, in Norway and is published ... , "Scientists have long observed that human and mouse ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... President , , EAST ... SVNT ) today announced that its Board ... Committee")to oversee the regulatory and pre-launch activities for the ... comprised of independent Board members Lee S. Simon, M.D. ...
... CITY, Nov. 19 UCN, Inc.,(Nasdaq: UCNN ), ... one year renewable agreement for inContact(R) with a leading,healthcare provider ... , This new customer ... Response) solution with call routing between two of the company,s,contact ...
... Stayhealthy, Inc. and EF,Recovery announced today that they ... Fire Rescue Wellness Corporation to bring,revolutionary health and fitness ... "The health and safety of our ... Fire Chief of South Kitsap Fire Rescue. "As our ...
... This month the hit television,show ,Living in Style, ... in Style, is a half-hour news magazine television,series and ... clinically,proven ability to reduce body fat and increase lean ... premier brand of health supplements to,the consumer and utilizes ...
... People in the middle of,separation or divorce ... traditions are shattered; the hope and joy that ... depression. This year,s,economic downturn will add even more ... facing already-difficult financial circumstances. , ...
... LONDON, Nov. 19 With issues around patient comfort ... need to,consider patients, relief and welfare. This is leading ... are being used for a greater,number of patients and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...
Cached Medicine News:Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 2Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 3Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 4Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 5Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 6Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 7Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 8Health News:Leading Healthcare Provider Signs Agreement With UCN for inContact 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 3Health News:Clarinol(TM) CLA and Puregels(R) Featured on Hit Television Show 'Living in Style' 2Health News:Clarinol(TM) CLA and Puregels(R) Featured on Hit Television Show 'Living in Style' 3Health News:Holiday Season Amplifies Hurt of Separation and Divorce: Economic Woes Add to Pressure 2Health News:Patient Temperature Management Systems Enjoying Wider Usage 2Health News:Patient Temperature Management Systems Enjoying Wider Usage 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: